Nektar PEG-Irinotecan Moves Into Phase II For Colorectal Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
By applying Nektar’s PEGylation technology to Camptosar, the drug may demonstrate more powerful and tolerable anti-tumor activity.
You may also be interested in...
Nektar Continues To Refocus With Sale Of Pulmonary Business To Novartis
CEO Howard Robin says firm now will focus fully on PEGylation and conjugate chemistry-based drug development.
Nektar Continues To Refocus With Sale Of Pulmonary Business To Novartis
CEO Howard Robin says firm now will focus fully on PEGylation and conjugate chemistry-based drug development.
Nektar Cuts Another 150 Jobs In Wake Of Exubera; Sharpens Therapeutic Focus
San Carlos, Calif., firm still shopping for new inhaled-insulin partner.